Trial Profile
A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress (Everolimus) Versus Rapamune (Sirolimus) in Combination With Low Dose Neoral(Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Antithymocyte globulin; Ciclosporin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 02 Nov 2021 Status changed from active, no longer recruiting to completed.
- 09 May 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2018.
- 09 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2018.